Doubts have been expressed by some Member States about the interaction of those provisions of Directive 2001/83/EC and Regulation (EC) No 726/2004 with the GMO legislation. In light of the urgent need of making vaccines or treatments for COVID-19 available to the public as soon as they are ready for this purpose and to avoid delays or uncertainties as regards the status of these products in certain Member States, it is appropriate that, where Member States adopt decisions pursuant to Article 5(1) and (2) of Directive 2001/83/EC or Article 83(1) of Regulation (EC) No 726/2004 concerning medicinal products containing or consisting of GMOs intended to treat or prevent COVID‐19, an environmental risk assessment or consent in accordance with Directive 2001/18/EC or Directive 2009/41/EC are not a prerequisite.
Recital 23, Regulation (EU) 2020/1043
In forcesince 15 Jul 2020